Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.38 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 4/20 | 0.38 |
| ▸ | RAB9A | P51151 | 4/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.38 |
| ▸ | TP53 | P04637 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | SCD | O00767 | 2/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.36 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.36 |
| ▸ | RELA | Q04206 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8033858 | 0.90 | ADORA2A (0.49) | HDAC6ALDH1A1KDRADORA2ANPC1 | |
| SCHEMBL8047828 | 0.89 | HDAC6 (0.44) | HDAC6ALDH1A1KDRADORA2APTPN2 | |
| SCHEMBL8049974 | 0.88 | RAB9A (0.51) | ALDH1A1ADORA2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL8047827 | 0.87 | NPC1 (0.41) | HDAC6ALDH1A1POLBKDRADORA2A | |
| SCHEMBL8041832 | 0.86 | RAB9A (0.53) | ALDH1A1KDRADORA2ANPC1RAB9A | |
| SCHEMBL8033698 | 0.84 | SMN1; SMN2 (0.42) | HDAC6ALDH1A1POLBKDRPTPN2 | |
| SCHEMBL8050490 | 0.81 | CCNE1 (0.41) | HDAC6ALDH1A1KDRADORA2APTPN2 | |
| SCHEMBL8046860 | 0.81 | POLB (0.38) | HDAC6ALDH1A1POLBKDRADORA2A | |
| SCHEMBL8047833 | 0.80 | NPC1 (0.40) | HDAC6ALDH1A1ADORA2ANPC1RAB9A | |
| SCHEMBL8042762 | 0.79 | NPC1 (0.41) | HDAC6ALDH1A1KDRNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150080381-A1 | METHODS OF TREATING ALOPECIA AND ACNE | IRONWOOD PHARMACEUTICALS, INC. | 2015-03-19 | — | — | US | claimed |
| US-8674115-B2 | CRTH2 modulators | IRONWOOD PHARMACEUTICALS, INC. (US) | 2014-03-18 | — | — | US | claimed |
| WO-2013155422-A1 | METHODS OF TREATING ALOPECIA AND ACNE | IRONWOOD PHARMACEUTICALS, INC. (US) | 2013-10-17 | — | — | WO | claimed |
| EP-2516416-A1 | CRTH2 MODULATORS | Ironwood Pharmaceuticals, Inc. (US) | 2012-10-31 | — | — | EP | claimed |
| WO-2011079007-A1 | CRTH2 MODULATORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2011-06-30 | — | — | WO | claimed |
| US-20110150834-A1 | CRTH2 MODULATORS | WELLS FARGO BANK, NATIONAL ASSOCIATION | 2011-06-23 | — | — | US | claimed |
| US-20150080381-A1 | METHODS OF TREATING ALOPECIA AND ACNE | IRONWOOD PHARMACEUTICALS, INC. | 2015-03-19 | — | — | US | disclosed |
| US-8674115-B2 | CRTH2 modulators | IRONWOOD PHARMACEUTICALS, INC. (US) | 2014-03-18 | — | — | US | disclosed |
| WO-2013155422-A1 | METHODS OF TREATING ALOPECIA AND ACNE | IRONWOOD PHARMACEUTICALS, INC. (US) | 2013-10-17 | — | — | WO | disclosed |
| CN-102822163-A | Crth2 modulators | IRONWOOD PHARMACEUTICALS INC | 2012-12-12 | — | — | CN | disclosed |
| EP-2516416-A1 | CRTH2 MODULATORS | Ironwood Pharmaceuticals, Inc. (US) | 2012-10-31 | — | — | EP | disclosed |
| WO-2011079007-A1 | CRTH2 MODULATORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2011-06-30 | — | — | WO | disclosed |
| US-20110150834-A1 | CRTH2 MODULATORS | WELLS FARGO BANK, NATIONAL ASSOCIATION | 2011-06-23 | — | — | US | disclosed |
| US-6080772-A | 2-AMINOTHIAZOLE TRIAZOLE OR TETRAZOLE COMPOUND FOR REGULATING PROTEIN TYROSINE PHOSPHATASE ACTIVITY | SUGEN, INC. (US) | 2000-06-27 | — | — | US | disclosed |
| WO-1998027092-A1 | THIAZOLE COMPOUNDS AND METHODS OF MODULATING SIGNAL TRANSDUCTION | SUGEN, INC. (US) | 1998-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150080381-A1 | METHODS OF TREATING ALOPECIA AND ACNE | CYP17A1, CYP21A2, HSD17B7 | HDAC6 970/4885ALDH1A1 75/4885POLB 1020/4885 |
| US-20110150834-A1 | CRTH2 MODULATORS | HRH2, HRH1, NR1H2 | HDAC6 2867/4885ALDH1A1 832/4885POLB 4079/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.